Eileen M Shore

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8430570/publications.pdf

Version: 2024-02-01

96 papers	7,879 citations	57758 44 h-index	51608 86 g-index
100 all docs	100 docs citations	100 times ranked	3877 citing authors

#	Article	IF	Citations
1	A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genetics, 2006, 38, 525-527.	21.4	1,079
2	Overexpression of an Osteogenic Morphogen in Fibrodysplasia Ossificans Progressiva. New England Journal of Medicine, 1996, 335, 555-561.	27.0	364
3	Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Human Mutation, 2009, 30, 379-390.	2.5	364
4	Heterotopic Ossification. Journal of the American Academy of Orthopaedic Surgeons, The, 2004, 12, 116-125.	2.5	307
5	Paternally Inherited Inactivating Mutations of theGNAS1Gene in Progressive Osseous Heteroplasia. New England Journal of Medicine, 2002, 346, 99-106.	27.0	284
6	Identification of Progenitor Cells That Contribute to Heterotopic Skeletogenesis. Journal of Bone and Joint Surgery - Series A, 2009, 91, 652-663.	3.0	278
7	Fibrodysplasia Ossificans Progressiva: Clinical and Genetic Aspects. Orphanet Journal of Rare Diseases, 2011, 6, 80.	2.7	231
8	Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. Nature Reviews Endocrinology, 2018, 14, 476-500.	9.6	224
9	Inherited human diseases of heterotopic bone formation. Nature Reviews Rheumatology, 2010, 6, 518-527.	8.0	220
10	Constitutively Activated ALK2 and Increased SMAD1/5 Cooperatively Induce Bone Morphogenetic Protein Signaling in Fibrodysplasia Ossificans Progressiva. Journal of Biological Chemistry, 2009, 284, 7149-7156.	3.4	184
11	The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. Journal of Clinical Investigation, 2009, 119, 3462-72.	8.2	178
12	Early Mortality and Cardiorespiratory Failure in Patients with Fibrodysplasia Ossificans Progressiva. Journal of Bone and Joint Surgery - Series A, 2010, 92, 686-691.	3.0	169
13	An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. Journal of Bone and Mineral Research, 2012, 27, 1746-1756.	2.8	157
14	The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment. Journal of Bone and Mineral Research, 2016, 31, 650-656.	2.8	157
15	Early Diagnosis of Fibrodysplasia Ossificans Progressiva. Pediatrics, 2008, 121, e1295-e1300.	2.1	151
16	Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1R206H Fibrodysplasia Ossificans Progressiva (FOP) Mutation. Journal of Bone and Mineral Research, 2016, 31, 1666-1675.	2.8	137
17	Dysregulated BMP Signaling and Enhanced Osteogenic Differentiation of Connective Tissue Progenitor Cells From Patients With Fibrodysplasia Ossificans Progressiva (FOP). Journal of Bone and Mineral Research, 2008, 23, 305-313.	2.8	135
18	Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva. Journal of Bone and Mineral Research, 2018, 33, 269-282.	2.8	118

#	Article	IF	Citations
19	Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP). Bone, 2008, 43, 427-433.	2.9	117
20	Bone morphogenetic protein 24 in early fibromatous lesions of fibrodysplasia ossificans progressiva. Human Pathology, 1997, 28, 339-343.	2.0	115
21	Deficiency of the Î±-Subunit of the Stimulatory G Protein and Severe Extraskeletal Ossification. Journal of Bone and Mineral Research, 2000, 15, 2074-2083.	2.8	110
22	Cellular Hypoxia Promotes Heterotopic Ossification by Amplifying BMP Signaling. Journal of Bone and Mineral Research, 2016, 31, 1652-1665.	2.8	110
23	Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis. DMM Disease Models and Mechanisms, 2012, 5, 756-762.	2.4	109
24	Fibrodysplasia Ossificans Progressiva (FOP), a Disorder of Ectopic Osteogenesis, Misregulates Cell Surface Expression and Trafficking of BMPRIA. Journal of Bone and Mineral Research, 2005, 20, 1168-1176.	2.8	103
25	Hematopoietic Stem-Cell Contribution to Ectopic Skeletogenesis. Journal of Bone and Joint Surgery - Series A, 2007, 89, 347-357.	3.0	102
26	Substance P signaling mediates BMP-dependent heterotopic ossification. Journal of Cellular Biochemistry, 2011, 112, 2759-2772.	2.6	99
27	The Genetics of Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 201-204.	0.8	98
28	Mast cell involvement in fibrodysplasia ossificans progressiva. Human Pathology, 2001, 32, 842-848.	2.0	96
29	The Phenotype of Fibrodysplasia Ossificans Progressiva. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 183-188.	0.8	94
30	Alk2 Regulates Early Chondrogenic Fate in Fibrodysplasia Ossificans Progressiva Heterotopic Endochondral Ossification. Stem Cells, 2014, 32, 1289-1300.	3.2	94
31	Developmental Anomalies of the Cervical Spine in Patients With Fibrodysplasia Ossificans Progressiva Are Distinctly Different From Those in Patients With Klippel-Feil Syndrome. Spine, 2005, 30, 1379-1385.	2.0	89
32	Functional Modeling of the ACVR1 (R206H) Mutation in FOP. Clinical Orthopaedics and Related Research, 2007, 462, 87-92.	1.5	86
33	TGF-Î² Family Signaling in Connective Tissue and Skeletal Diseases. Cold Spring Harbor Perspectives in Biology, 2017, 9, a022269.	5.5	86
34	Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP). Journal of Bone and Mineral Metabolism, 2008, 26, 521-530.	2.7	73
35	Proximal Tibial Osteochondromas in Patients with Fibrodysplasia Ossificans Progressiva. Journal of Bone and Joint Surgery - Series A, 2008, 90, 366-374.	3.0	71
36	Influenza-like Viral Illnesses and Flare-ups of Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 2004, 423, 275-279.	1.5	68

#	Article	IF	Citations
37	Progressive osseous heteroplasia: diagnosis, treatment, and prognosis. The Application of Clinical Genetics, 2015, 8, 37.	3.0	67
38	GNAS1 Mutation and Cbfa1 Misexpression in a Child with Severe Congenital Platelike Osteoma Cutis. Journal of Bone and Mineral Research, 2000, 15, 2063-2073.	2.8	66
39	The Immunological Contribution to Heterotopic Ossification Disorders. Current Osteoporosis Reports, 2015, 13, 116-124.	3.6	66
40	In vitro Analyses of the Dysregulated R206H ALK2 Kinase-FKBP12 Interaction Associated with Heterotopic Ossification in FOP. Cells Tissues Organs, 2011, 194, 291-295.	2.3	65
41	The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling. Cytokine and Growth Factor Reviews, 2009, 20, 399-407.	7.2	60
42	Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatric Endocrinology Reviews, 2013, 10 Suppl 2, 437-48.	1.2	59
43	Granting immunity to FOP and catching heterotopic ossification in the Act. Seminars in Cell and Developmental Biology, 2016, 49, 30-36.	5.0	54
44	Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders. Cytokine and Growth Factor Reviews, 2016, 27, 93-104.	7.2	51
45	ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant. Human Molecular Genetics, 2014, 23, 5364-5377.	2.9	48
46	Immunological Features of Fibrodysplasia Ossificans Progressiva and the Dysregulated BMP4 Pathway. Clinical Reviews in Bone and Mineral Metabolism, 2005, 3, 189-194.	0.8	45
47	Bone Morphogenetic Protein-4 Regulation in Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 2003, 408, 331-343.	1.5	43
48	Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients. Hormone Research in Paediatrics, 2020, 93, 182-196.	1.8	42
49	Variable signaling activity by FOP ACVR1 mutations. Bone, 2018, 109, 232-240.	2.9	38
50	CNS demyelination in fibrodysplasia ossificans progressiva. Journal of Neurology, 2012, 259, 2644-2655.	3.6	37
51	IL15RA is required for osteoblast function and bone mineralization. Bone, 2017, 103, 20-30.	2.9	37
52	Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP). Bone, 2018, 109, 218-224.	2.9	36
53	Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP). Expert Opinion on Orphan Drugs, 2017, 5, 291-294.	0.8	34
54	Fibrodysplasia ossificans progressiva: a human genetic disorder of extraskeletal bone formation, orâ€"how does one tissue become another?. Wiley Interdisciplinary Reviews: Developmental Biology, 2012, 1, 153-165.	5.9	33

#	Article	IF	Citations
55	Multiâ€system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1) Tj ETQq1 1 0.784314 rgBT /Ov 2265-2271.	1.2	33
56	Delayed hypertrophic differentiation of epiphyseal chondrocytes contributes to failed secondary ossification in mucopolysaccharidosis VII dogs. Molecular Genetics and Metabolism, 2015, 116, 195-203.	1.1	31
57	Role of Altered Signal Transduction in Heterotopic Ossification and Fibrodysplasia Ossificans Progressiva. Current Osteoporosis Reports, 2011, 9, 83-88.	3.6	30
58	ACVR1^{R206H} FOP mutation alters mechanosensing and tissue stiffness during heterotopic ossification. Molecular Biology of the Cell, 2019, 30, 17-29.	2.1	30
59	Elevated BMP and Mechanical Signaling Through YAP1/RhoA Poises FOP Mesenchymal Progenitors for Osteogenesis. Journal of Bone and Mineral Research, 2019, 34, 1894-1909.	2.8	29
60	Fibrodysplasia ossificans progressiva in two half-sisters: Evidence for maternal mosaicism. , 1996, 61, 320-324.		28
61	Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis. Bone, 2020, 140, 115539.	2.9	26
62	Fibrodysplasia ossificans progressiva mutant ACVR1 signals by multiple modalities in the developing zebrafish. ELife, 2020, 9, .	6.0	26
63	Characterization of Bone Morphogenetic Protein 4 Receptor in Fibrodysplasia Ossificans Progressiva. Clinical Orthopaedics and Related Research, 1998, 346, 38???45.	1.5	24
64	GsÎ± Controls Cortical Bone Quality by Regulating Osteoclast Differentiation via cAMP/PKA and Î²-Catenin Pathways. Scientific Reports, 2017, 7, 45140.	3.3	24
65	Pathogenic ACVR1^{R206H} activation by Activin Aâ€induced receptor clustering and autophosphorylation. EMBO Journal, 2021, 40, e106317.	7.8	24
66	Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish. Bone, 2018, 109, 225-231.	2.9	23
67	Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva. Bone, 2020, 130, 115116.	2.9	22
68	Osteogenic Induction in Hereditary Disorders of Heterotopic Ossification. Clinical Orthopaedics and Related Research, 2000, 374, 303-316.	1.5	20
69	Molecular profiling of failed endochondral ossification in mucopolysaccharidosis VII. Bone, 2019, 128, 115042.	2.9	16
70	Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop. Frontiers in Endocrinology, 2021, 12, 732728.	3.5	15
71	Osteoinductive signals and heterotopic ossification. Journal of Bone and Mineral Research, 2011, 26, 1163-1165.	2.8	14
72	<scp>BMP</scp> signaling and skeletal development in fibrodysplasia ossificans progressiva (<scp>FOP</scp>). Developmental Dynamics, 2022, 251, 144-157.	1.8	12

#	Article	IF	Citations
73	Dynamics of skeletal muscle-resident stem cells during myogenesis in fibrodysplasia ossificans progressiva. Npj Regenerative Medicine, 2022, 7, 5.	5.2	10
74	The congenital great toe malformation of fibrodysplasia ossificans progressiva? - A close call. European Journal of Medical Genetics, 2017, 60, 399-402.	1.3	9
75	Ablation of Gsî± signaling in osteoclast progenitor cells adversely affects skeletal bone maintenance. Bone, 2018, 109, 86-90.	2.9	9
76	The Developmental Phenotype of the Great Toe in Fibrodysplasia Ossificans Progressiva. Frontiers in Cell and Developmental Biology, 2020, 8, 612853.	3.7	9
77	Analog Method for Radiographic Assessment of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva. Academic Radiology, 2017, 24, 321-327.	2.5	8
78	Differential Vascularity in Genetic and Nonhereditary Heterotopic Ossification. International Journal of Surgical Pathology, 2019, 27, 859-867.	0.8	8
79	Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva. Methods in Molecular Biology, 2019, 1891, 247-255.	0.9	8
80	Identification of the Identical Human Mutation in ACVR1 in 2 Cats With Fibrodysplasia Ossificans Progressiva. Veterinary Pathology, 2019, 56, 614-618.	1.7	7
81	Dysregulated BMP signaling through ACVR1 impairs digit joint development in fibrodysplasia ossificans progressiva (FOP). Developmental Biology, 2021, 470, 136-146.	2.0	7
82	A case report of mesenteric heterotopic ossification: Histopathologic and genetic findings. Bone, 2018, 109, 56-60.	2.9	6
83	Pregnancy in fibrodysplasia ossificans progressiva. Obstetric Medicine, 2012, 5, 35-38.	1.1	5
84	Severe digital malformations in a rare variant of fibrodysplasia ossificans progressiva. American Journal of Medical Genetics, Part A, 2019, 179, 1310-1314.	1.2	5
85	Effects of lithium administration on vertebral bone disease in mucopolysaccharidosis I dogs. Bone, 2022, 154, 116237.	2.9	3
86	An ACVR1 R375P pathogenic variant in two families with mild fibrodysplasia ossificans progressiva. American Journal of Medical Genetics, Part A, 2021, , .	1.2	3
87	Genetics and future therapy prospects of fibrodysplasia ossificans progressiva. Medizinische Genetik, 2020, 31, 391-396.	0.2	2
88	Cover Image, Volume 179A, Number 7, July 2019. , 2019, 179, .		2
89	Gnas Inactivation Alters Subcutaneous Tissues in Progression to Heterotopic Ossification. Frontiers in Genetics, 2021, 12, 633206.	2.3	2
90	Comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'. ELife, 2019, 8, .	6.0	2

#	Article	IF	Citations
91	Heterotopic Ossification: The Keys to the Kingdom. Bone, 2018, 109, 1-2.	2.9	1
92	<scp>Nonclassic</scp> fibrodysplasia ossificans progressiva: A child from Angola with an <scp>ACVR1^{G328E}</scp> variant. American Journal of Medical Genetics, Part A, 2021, 185, 2572-2575.	1.2	1
93	The complex craniofacial signature of fibrodysplasia ossificans progressiva: Whose handwriting is it?. American Journal of Medical Genetics, Part A, 2012, 158A, 2979-2980.	1.2	0
94	Reply to: Macrophages Driving Heterotopic Ossification: Convergence of Genetically-Driven and Trauma-Driven Mechanisms. Journal of Bone and Mineral Research, 2018, 33, 367-368.	2.8	0
95	Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva â€“ How Does One Tissue Become Another?. FASEB Journal, 2018, 32, 361.2.	0.5	0
96	Heterotopic ossification â€•replacement of one tissue with another. FASEB Journal, 2022, 36, .	0.5	0